Avaliação da eficácia do cidofovir na papilomatose respiratória recorrente juvenil

Abstract

The efficacy of cidofovir in juvenile recurrent respiratory papillomatosis (JRRP) remains uncertain due to the lack of published case-control studies. Aim:To establish factors affecting the progression of JRRP prognosis, and to evaluate cidofovir for eradicating JRRP.Study Design: Retrospective.

<p>Juvenile-Onset Recurrent Respiratory Papillomatosis Diagnosis and Management – A Developing Country Review</p>

“…While uncontrolled and retrospective studies have shown intralesional cidofovir to be effective for RRP with approximately 40-50% of patients achieving remission, a systematic review on adjuvant antiviral therapy for the treatment of RRP identified only one randomized double-blind, placebo-controlled trial of intralesional cidofovir administered at the time of surgical debulking with significant clinical improvements in both the cidofovir and placebo groups and no significant difference between the two groups. [76][77][78][79][80] Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by binding to and inhibiting the biological activity of human vascular endothelial growth factor A (VEGF-A). 81 Intralesional bevacizumab has been shown to prolong the intersurgical interval in small case series, 81 while systemic bevacizumab has been shown to be of benefit in patients with highly aggressive disease and those with pulmonary involvement.…”